Erkan, ArzuPirildar, SebnemAcarer, AhmetAkdeniz, Fisun2019-10-272019-10-2720111017-7833https://doi.org/10.5455/bcp.20111029071711https://hdl.handle.net/11454/45805Efficacy of low-dose pramipexole augmentation in the treatment of refractory psychotic depression complicated with tardive dyskinesia: a case report Tardive dyskinesia (TD) is a severe complication of antipsychotic treatment. Pramipexole can be effective in the treatment of TD due to its D3 dopamine receptor agonist effect. Studies conducted in bipolar depression and treatment-resistant depression (TRD), support the antidepressant effect of pramipexole. Here we present the case of a 55 year-old female. For the treatment of depression, she received antidepressants, anxiolytics and antipsychotics for 2.5 years. When severe bruxism, fidgeting, and serious functional impairment emerged, she was re-hospitalized and diagnosed with TRD and TD. Several combinations of antidepressants, anxiolytic, and antipsychotics were administered. The depression improved partially, but hypochondriac preoccupations and dyskinesia persisted. At the sixth month, pramipexole 0.125 mg/day was added to sertraline 200 mg/day, amitriptyline 60 mg/day, clonazepam 2 mg/day, and biperiden 4 mg/day. The depression and dyskinesia improved and she was discharged. TRD and TD improved within the first 4 weeks of pramipexole administration and no relapse was observed. Pramipexole is a promising agent in the treatment of TRD and TD.en10.5455/bcp.20111029071711info:eu-repo/semantics/openAccessPramipexoledepressionpsychoticdyskinesiadrug-inducedArticle214353355WOS:000297959300008Q4